Establishment Labs (NASDAQ:ESTA) Hits New 52-Week High – What’s Next?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares hit a new 52-week high on Wednesday . The company traded as high as $89.36 and last traded at $89.0290, with a volume of 117060 shares trading hands. The stock had previously closed at $87.01.

Analysts Set New Price Targets

Several analysts have commented on ESTA shares. Canaccord Genuity Group raised their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. TD Cowen restated a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. Needham & Company LLC lifted their price target on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Stephens increased their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, Mizuho raised their price objective on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Establishment Labs presently has an average rating of “Moderate Buy” and a consensus target price of $87.14.

Establishment Labs Stock Up 1.2%

The stock’s 50 day simple moving average is $72.24 and its two-hundred day simple moving average is $69.98. The firm has a market cap of $2.59 billion, a P/E ratio of -59.24 and a beta of 1.11. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The company had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. During the same quarter in the previous year, the company earned ($0.70) EPS. The business’s quarterly revenue was up 44.7% on a year-over-year basis. As a group, research analysts forecast that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the sale, the director directly owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 292,500 shares of company stock valued at $20,591,021 over the last 90 days. Insiders own 9.99% of the company’s stock.

Hedge Funds Weigh In On Establishment Labs

Several large investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in Establishment Labs by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after purchasing an additional 299 shares in the last quarter. Brian Low Financial Group LLC increased its stake in Establishment Labs by 10.2% during the 1st quarter. Brian Low Financial Group LLC now owns 4,598 shares of the company’s stock valued at $261,000 after purchasing an additional 424 shares in the last quarter. KBC Group NV bought a new stake in Establishment Labs during the 1st quarter valued at about $28,000. Handelsbanken Fonder AB raised its holdings in Establishment Labs by 7.3% in the fourth quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock worth $641,000 after buying an additional 600 shares during the last quarter. Finally, Swiss National Bank raised its holdings in Establishment Labs by 1.8% in the fourth quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $2,492,000 after buying an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.